By Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB
The US Supreme Court has mutilated US Patent law with the law of nature doctrine created from the decisions Mayo v. Prometheus and AMP v. Myriad Genetics. Since then, the US-PTO has implemented guidelines, and the highest patent court in the US, the CAFC, has issued numerous decisions applying these Supreme Court decisions, making it hard or impossible to obtain useful patent protection and/or enforce it, in particular for inventions directed to diagnostic methods, or directed to naturally occurring substances.
ADVERTISEMENT
Tackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
Together with the EIB, five of the EUs largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
The European Biotechnology Science & Industry Guide provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry, and is now also available as part of the BIOCOM app!
Dutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III.
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos pipeline and drug discovery platform.
Its no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. For both patients and companies, improving productivity in the area would bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – could make the process faster, safer and cheaper. tg
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.